Expired activity
Please go to the PowerPak homepage and select a course.

Triglyceride-rich Lipoproteins and Cardiovascular Disease: Importance and Management Update for Pharmacists

This activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Amarin Corporation.


Daniel E. Hilleman, PharmD
Professor of Pharmacy, Department of Pharmacy Practice
Creighton University School of Pharmacy and Health Professions
Research Pharmacist
Creighton University Cardiac Center
Creighton University School of Medicine
Omaha, Nebraska


Daniel E. Hilleman, PharmD, hereby states that he has no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.

The following reviewer, Eric K. Gupta, PharmD, BCPS, CLS, FCPhA, FNLA, hereby states the following financial relationships or relationships to products or devices with a commercial interest related to the content of this activity: member of the speakers' bureau for Sanofi; receives other financial/material support from Amarin Corporation.

Susanne Batesko, RN, BSN, Michele Salernitano, and Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-16-009-H01-P
Credits: 2.0 hours (0.20 ceu)

Published: February 29, 2016
Expires: February 28, 2018
Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 120 minutes


This accredited activity has been designed for pharmacists.


During the period February 29, 2016 through February 28, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


The goal of this activity is to educate pharmacists about triglyceride-rich lipoproteins and explain how they contribute to the development of atherosclerosis and cardiovascular disease, including discussion about the currently available therapeutic options.


Upon completion of this activity, participants should be better able to:

  1. Define triglyceride-rich lipoprotein types and explain the impact they have on the risk for cardiovascular disease;
  2. Review the latest clinical trial data regarding genetic findings and the interaction between lipoproteins and inflammation on the development of atherosclerotic disease;
  3. Identify currently recommended lifestyle therapy changes in the management of elevated triglycerides and triglyceride-rich lipoproteins;
  4. Recognize the mechanism of action of triglyceride-lowering therapies, including the latest adjunct therapies to statin therapy;
  5. Relate differences among the various EPA and DHA omega-3 fatty acid formulations, including dietary supplements on triglyceride-rich lipoproteins, atherosclerosis, and inflammation;
  6. Discuss the most effective methods for counseling patients with hypertriglyceridemia about lifestyle modifications and treatment options; and
  7. Develop competence on incorporating the medical therapy management (MTM) of triglyceride-rich lipoprotein into action plans.


Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC and Amarin Corporation. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without an evaluation of their patients' conditions and current medications, including the identification of possible contraindications regarding the dangers of use and a review of any applicable manufacturer's product information, as well as a comparison with the recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.